Randomised controlled trial for efficacy of unfractionated heparin (UFH) versus low molecular weight heparin (LMWH) in thrombo-prophylaxis. 2013

Sandeep V Ishi, and M Lakshmi, and Shailesh T Kakde, and Kirti C Sabnis, and Manjeera Jagannati, and T S Girish, and L Jeyaseelan, and A M Cherian

OBJECTIVE To study if low dose Unfractionated heparin (UFH) is as effective and safe as Low-molecular weight heparin (LMWH) and also economical as a prophylactic agent for venous thromboembolism in medically ill patients. METHODS A prospective double blind randomised controlled trial consisting of 92 patients fulfilling the inclusion criteria who were admitted to Bangalore Baptist Hospital, Bengaluru, between March 2008 and July 2009 were randomised to receive Unfractionated heparin (UFH) or Low-molecular weight heparin (LMWH). RESULTS The result based on intention to treat (ITT)analysis with best outcome scenario: in the UFH arm there were 47 (97.9%) patients who had not developed DVT/PE as compared to 42 (95.5%) in the LMWH arm. The difference in proportion of patients who had not developed DVT/PE between UFH and LMWH was 2.4% (-5.0, 9.8). The results based on per protocol analysis: In the UFH arm there were 44 (97.8%) patients who had not developed DVT/PE as compared to 39 (95.1%) in the LMWH arm. The difference in proportion of patients who had not developed DVT/PE between the UFH and LMWH arm was 2.7% (-5.2, 10.5). Patients on UFH had higher major bleeding complications 4 (8.9%) as compared to 0 in LMWH arm. But with respect to other complications like thrombocytopenia (HIT) and mild or minimal bleeding both arms were comparable. CONCLUSIONS This study has demonstrated that low dose UFH is as effective as LMWH as a prophylactic agent for venous thromboembolism in medically ill patients and economical also.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D011655 Pulmonary Embolism Blocking of the PULMONARY ARTERY or one of its branches by an EMBOLUS. Pulmonary Thromboembolism,Thromboembolism, Pulmonary,Embolism, Pulmonary,Embolisms, Pulmonary,Pulmonary Embolisms,Pulmonary Thromboembolisms,Thromboembolisms, Pulmonary
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D005260 Female Females
D006493 Heparin A highly acidic mucopolysaccharide formed of equal parts of sulfated D-glucosamine and D-glucuronic acid with sulfaminic bridges. The molecular weight ranges from six to twenty thousand. Heparin occurs in and is obtained from liver, lung, mast cells, etc., of vertebrates. Its function is unknown, but it is used to prevent blood clotting in vivo and vitro, in the form of many different salts. Heparinic Acid,alpha-Heparin,Heparin Sodium,Liquaemin,Sodium Heparin,Unfractionated Heparin,Heparin, Sodium,Heparin, Unfractionated,alpha Heparin
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000925 Anticoagulants Agents that prevent BLOOD CLOTTING. Anticoagulant Agent,Anticoagulant Drug,Anticoagulant,Anticoagulant Agents,Anticoagulant Drugs,Anticoagulation Agents,Indirect Thrombin Inhibitors,Agent, Anticoagulant,Agents, Anticoagulant,Agents, Anticoagulation,Drug, Anticoagulant,Drugs, Anticoagulant,Inhibitors, Indirect Thrombin,Thrombin Inhibitors, Indirect

Related Publications

Sandeep V Ishi, and M Lakshmi, and Shailesh T Kakde, and Kirti C Sabnis, and Manjeera Jagannati, and T S Girish, and L Jeyaseelan, and A M Cherian
July 2017, The journal of trauma and acute care surgery,
Sandeep V Ishi, and M Lakshmi, and Shailesh T Kakde, and Kirti C Sabnis, and Manjeera Jagannati, and T S Girish, and L Jeyaseelan, and A M Cherian
January 1997, Haemostasis,
Sandeep V Ishi, and M Lakshmi, and Shailesh T Kakde, and Kirti C Sabnis, and Manjeera Jagannati, and T S Girish, and L Jeyaseelan, and A M Cherian
July 1999, Clinical & experimental metastasis,
Sandeep V Ishi, and M Lakshmi, and Shailesh T Kakde, and Kirti C Sabnis, and Manjeera Jagannati, and T S Girish, and L Jeyaseelan, and A M Cherian
March 2004, European journal of medical research,
Sandeep V Ishi, and M Lakshmi, and Shailesh T Kakde, and Kirti C Sabnis, and Manjeera Jagannati, and T S Girish, and L Jeyaseelan, and A M Cherian
July 2012, European journal of neurology,
Sandeep V Ishi, and M Lakshmi, and Shailesh T Kakde, and Kirti C Sabnis, and Manjeera Jagannati, and T S Girish, and L Jeyaseelan, and A M Cherian
January 2012, Journal of hospital medicine,
Sandeep V Ishi, and M Lakshmi, and Shailesh T Kakde, and Kirti C Sabnis, and Manjeera Jagannati, and T S Girish, and L Jeyaseelan, and A M Cherian
December 2022, Clinical neurology and neurosurgery,
Sandeep V Ishi, and M Lakshmi, and Shailesh T Kakde, and Kirti C Sabnis, and Manjeera Jagannati, and T S Girish, and L Jeyaseelan, and A M Cherian
September 2014, Acta oncologica (Stockholm, Sweden),
Sandeep V Ishi, and M Lakshmi, and Shailesh T Kakde, and Kirti C Sabnis, and Manjeera Jagannati, and T S Girish, and L Jeyaseelan, and A M Cherian
January 1998, The New England journal of medicine,
Sandeep V Ishi, and M Lakshmi, and Shailesh T Kakde, and Kirti C Sabnis, and Manjeera Jagannati, and T S Girish, and L Jeyaseelan, and A M Cherian
January 1998, The New England journal of medicine,
Copied contents to your clipboard!